CD47型
纳米医学
光敏剂
免疫疗法
化学
免疫系统
癌症研究
生物物理学
材料科学
纳米颗粒
纳米技术
细胞
生物化学
免疫学
医学
生物
有机化学
作者
Yan Lu,Yonghua Gong,Xianghui Zhu,Xia Dong,Dunwan Zhu,Guilei Ma
标识
DOI:10.1002/adhm.202102712
摘要
Abstract Here, the authors propose a light‐activated reactive oxygen species (ROS)‐responsive nanoplatform that can boost immunogenic cell death (ICD) to release “eat me” signals, and improve CD47‐blocking immunotherapy by tumor‐targeted codelivery of photosensitizer IR820 and anti‐CD47 antibody ( α CD47). Human serum albumin and α CD47 are first constructed into a single nanoparticle using ROS‐responsive linkers, which are further conjugated with photosensitizer IR820 via a matrix metalloproteinase‐sensitive peptide as linker and then modified with poly(ethylene glycol) on the surface of the obtained nanoparticles. When exposed to the first wave of near‐infrared (NIR) laser irradiation, the obtained nanoplatform (M‐IR820/ α CD47@NP) can generate ROS, which triggers nanoparticles dissociation and thus, facilitates the release of α CD47 and IR820. The second wave of NIR laser irradiation is subsequently used to perform phototherapy and induce ICD of tumor cells. An in vitro cellular study shows that M‐IR820/ α CD47@NP can stimulate dendritic cells activation while simultaneously enhancing the phagocytic activity of macrophage against tumor cells. In 4T1 tumor‐bearing mice, M‐IR820/ α CD47@NP‐mediated combination of phototherapy and CD47 blockade can effectively induce the synergistic antitumor immune responses to inhibit the growth of tumors and prevent local tumor recurrence. This work offers a promising strategy to improve the CD47‐blocking immunotherapy efficacy using α CD47 nanomedicine.
科研通智能强力驱动
Strongly Powered by AbleSci AI